Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OMED

OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis

OncoMed Pharmaceuticals logo

About OncoMed Pharmaceuticals Stock (NASDAQ:OMED)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$0.89
52-Week Range
N/A
Volume
1,201 shs
Average Volume
768,904 shs
Market Capitalization
$34.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

Receive OMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OMED Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

OMED Stock Analysis - Frequently Asked Questions

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. OncoMed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.14% and a negative net margin of 18.24%.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol-Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS).

Company Calendar

Last Earnings
11/01/2018
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OMED
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$44.42 million
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$34.43 million
Optionable
Optionable
Beta
1.86
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:OMED) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners